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Abstract Proteinases produced by vascular endothelial cells are 
expected to play important roles in many biological processes. 
Here we report that human vascular endothelial cells express 
trypsinogen-2 mRNA and its protein product in culture. The 
trypsinogen production was stimulated by a tumor promoter and 
associated with cell growth. In situ hybridization analysis showed 
that the trypsinogen gene was significantly expressed in vascular 
endothelial cells around gastric tumors and in patients with 
disseminated intravascular coagulation (DIC). These results 
suggest the possible roles of endothelial cell-derived trypsin in 
tumor angiogenesis and abnormal blood coagulation. 
© 1997 Federation of European Biochemical Societies. 
Key words: Vascular endothelial cell; Trypsin; Angiogenesis; 
Disseminated intravascular coagulation 
1. Introduction 
Endothelial cells contact with blood and directly regulate 
many important physiological and pathological processes such 
as blood coagulation, angiogenesis, tumor metastasis, and 
control of blood pressure [1-4]. Proteinases secreted from en-
dothelial cells are believed to be involved in these processes. 
Previous studies have shown that vascular endothelial cells 
produce two plasminogen activators (PA) and some matrix 
metalloproteinases (MMP) [5,6]. 
In a step of angiogenesis, activated endothelial cells pene-
trate into the vascular basement membrane, migrate through 
the underlying extracellular matrix (ECM), and proliferate to 
form new capillaries. Proteinases secreted by endothelial cells 
are thought to play a critical role in the degradation of the 
basement membrane and interstitial matrix proteins. The pro-
teinase production by endothelial cells are stimulated by an-
giogenic cytokines such as basic-fibroblast growth factor (b-
F G F ) , transforming growth factor-cc (TGF-oc) and epidermal 
growth factor (EGF) , inflammatory mediators such as tumor 
necrosis factor-a (TNF-oc) and interleukin-1 (IL-1), and the 
tumor promoter 12-0-tetradecanoylphorbol-13-acetate (TPA) 
[7-9]. 
Vascular endothelial cells closely participate in the blood 
coagulation system. Under some pathological conditions, ac-
tivated vascular endothelial cells initiate the extrinsic coagu-
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Abbreviations: bp, base pair; DIC, disseminated intravascular coagu-
lation; HUVEC, human umbilical vein endothelial cell(s); MMP, 
matrix metalloproteinase; RT-PCR, reverse transcription/polymerase 
chain reaction; TPA, 12-0-tetradecanoylphorbol-13-acetate 
lation pathway [1,2]. Tissue factor on the endothelial cell sur-
faces binds factor Vi la , and the tissue factor-factor Vi l a 
complex then triggers the following proteinase cascade. How-
ever, it is not clear what proteinases activate factors VII to 
V i l a in vivo. On the other hand, during the course of tumor 
metastasis, metastatic tumor cells must invade into blood ves-
sels. Proteinases produced by endothelial cells and smooth 
muscle cells are expected to play some roles in the steps of 
intravasation and extravasation of metastatic tumor cells. 
We have previously reported that some types of human 
cancer cells secrete pancreatic trypsinogens, which can be ac-
tivated by enterokinase [10-12]. In this study, we analyzed 
proteinases secreted by two kinds of human vascular endothe-
lial cells ( H U V E C and MvEC), and found that vascular en-
dothelial cells expressed trypsin in vitro and in vivo. 
2. Materials and methods 
2.1. Cell culture 
Human umbilical vein endothelial cells (HUVEC) were prepared 
from fresh umbilical cords by trypsin treatment [13], and dermal mi-
crovascular endothelial cells (MvEC) were purchased from Cell Sys-
tems (Kirkland, WA). HUVEC and MvEC were maintained as de-
scribed before [13]. These cultured cells were characterized as 
endothelial cells by their immunochemical staining for von Willebrand 
factor antigen and by the typical tightpacking monolayer morphol-
ogy-
2.2. Gelatin zymography and immunoblotting 
Gelatin zymography was performed as described before [10]. Se-
rum-free conditioned media were prepared from confluent cultures 
of HUVEC and MvEC incubated for 48 h in serum-free MCDB 
107 medium (Kyokuto; Tokyo, Japan). The conditioned media were 
concentrated about 50-fold by ammonium sulfate at 80% saturation 
and dialyzed against 20 mM Tris-HCl buffer (pH 7.5) as described 
previously [10]. For activation of trypsinogen, 15 ill of the concen-
trated conditioned media ( ~ 5 mg protein/ml) was mixed with 2 \iX of 
50 iig/ml enterokinase (biozyme; South Wales, UK) and 4 ill of 5 mM 
CaCl2 and incubated at 37°C for 1 h, followed by SDS treatment. 
Immunoblotting was performed with rabbit polyclonal antibody 
against human trypsin (Athens Research and Technology; Athens, 
G A) by the previously reported method [10], except that the antigen 
was detected by the enhanced chemiluminescence method with an 
Amersham ECL kit (Buckinghamshire, UK). 
2.3. Northern blotting and RT-PCR 
Analyses of trypsinogen mRNA by Northern blotting and RT-PCR 
were carried out by the previously reported methods [12]. Total RNA 
was extracted from HUVEC, MvEC and STKM-1 cells. Twenty mi-
crograms of each RNA sample was separated on a 0.8% agarose gel, 
blotted onto a nylon membrane, and hybridized with a 32P-labeled 
human trypsinogen-1 cDNA probe. For RT-PCR analysis, the follow-
ing two primers with an EcoKI linker were designed: TRY1 [5'-AC-
GAATTCACAAGTCCCGCATCCAG-3'] and TRY2 [5'-AC-
GAATTCCCACCAGAATCACCCTG-3'], which corresponded to 
nucleotides 200-216 and 595-611, respectively, of human trypsino-
gen-1 cDNA [14]. The nucleotide sequences of the two primers were 
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Fig. 1. Identification of trypsinogen produced by human vascular endothelial cells in culture. A: Gelatin zymography in the absence of Ca2+ of 
conditioned media of HUVEC and MvEC which were pre-incubated without (—) or with (+) enterokinase (EK). An arrow indicates the gelati-
nolytic band of a trypsin-like enzyme (25 kDa). B: Northern blotting analysis of trypsinogen mRNA in HUVEC, MvEC and STKM-1 (human 
gastric carcinoma cell line). Upper panel (Northern blot): Tryp. indicates the band of human trypsinogen mRNA of about 850 bases. Lower 
panel (ethidium bromide staining of RNAs): Ordinate indicates the positions of 18S and 28S ribosomal RNAs. STKM-1 cells, which produce 
trypsinogen-1 and -2, were used as a positive control. C: Polyacrylamide gel electrophoresis of RT-PCR product from HUVEC RNA before 
(—) or after (+) treatment with Sacl restriction enzyme. RT-PCR was done with RNAs from HUVEC and STKM-1 using a specific primer set 
designed for trypsinogen-1 and -2 mRNAs. Plasmid DNAs coding for human trypsinogen-1 and -2 were also amplified with the same primer 
set as positive controls. The amplified DNA fragment of 420 bp from human trypsinogen-1 cDNA, but not that from trypsinogen-2 cDNA, 
was cleaved into two fragments of 270 and 150 bp by Sacl. The DNA fragment from STKM-1 RNA was partially cleaved into the two frag-
ments by the enzyme, whereas that from HUVEC RNA was not cleaved at all. 
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Fig. 2. Cell growth-dependent expression of trypsinogen gene in HU-
VEC. HUVEC were inoculated at a density of 3.5 XlO4 in 35-mm 
dishes with 2 ml of MCDB 107 plus 10% fetal calf serum (FCS). 
After incubation for 1, 3, 5, 7, 9 and 13 days, the cells were har-
vested and total RNA was isolated therefrom and subjected to 
Northern blotting. A : Time course of trypsinogen mRNA level after 
cell inoculation. Upper panel: Northern blot of trypsinogen mRNA 
at 850 bases. Lower panel: Ethidium bromide staining pattern of 
18S and 28S ribosomal RNAs. B: Growth curve of HUVEC (o) 
and relative level of trypsinogen mRNA (•). The level of trypsino-
gen mRNA was quantified with a BAS 2000 Bioimage analyzer 
(Fuji Film; Tokyo). Each point represents the average for duplicate 
cultures. Essentially the same result was obtained in a repeated ex-
periment. 
common to trypsinogens-1 and -2, but not to the other trypsinogens. 
Only the RT-PCR product from trypsinogen-1 transcript contained a 
Sac\ cleavage site. Five micrograms of total RNA was reverse-
transcrbed using Mo-MLV reverse transcriptase and then subjected 
to the PCR with the primers. The PCR products were digested by 40 
U of Sacl restriction enzyme (Takara; Shiga, Japan) at 37°C for 1 h, 
Fig. 3. Effect of TPA treatment on trypsinogen expression in HU-
VEC. A: Time course of trypsinogen mRNA level after TPA treat-
ment. B: Gelatin zymography of trypsinogen secreted by HUVEC. 
C: Immunoblotting analysis of trypsinogen secreted by HUVEC. 
HUVEC were incubated with (+) or without ( - ) 100 ng/ml TPA in 
the serum-containing medium for the indicated lengths of time (A) 
or in serum-free medium for 2 days (B,C). Northern blotting was 
carried out as described in Fig. 2. Gelatin zymography and immu-
noblotting were carried out after the enterokinase treatment of the 
concentrated conditioned medium as described in Section 2. 
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followed by electrophoresis on a 5% polyacrylamide gel. For nucleo-
tide sequencing, the RT-PCR product of 420 bp was electrophoreti-
cally separated and cloned into an EcoKl site of pGEM-3Zf(+) plas-
mid vector (Promega; Madison, WI). The nucleotide sequences of the 
cloned DNA fragments were determined by the dideoxynucleotide 
method with a Sequenase Version 2.0 kit (US Biochemicals; Cleve-
land, OH). 
2.4. In situ hybridization 
Surgically resected tissues were immediately fixed in 10% formalin. 
The paraffin-embedded sections were mounted on aminoacyl silane-
coated glass slides and used for in situ hybridization. A cDNA frag-
ment (nucleotides 131^482 in [14]) of human trypsinogen-1 was sub-
cloned into pGEM-3Zf(+) plasmid vector. Sense and antisense RNA 
probes were transcribed in vitro with T7 or SP6 RNA polymerase 
from the linearized plasmid (cleaved by EcoRI and Hindlll, respec-
tively) using digoxigenin-labeled UTP according to the manufacture's 
manual. In situ hybridization with the RNA probes was carried out as 
reported previously [15]. The hybridized signals were visualized by the 
alkaline phosphatase reaction. The tissue sections were counter-
stained with methylgreen. 
3. Results and discussion 
3.1. Expression of trypsinogen by cultured vascular endothelial 
cells 
To survey proteinases secreted by endothelial cells, serum-
free culture media conditioned by human umbilical vein en-
dothelial cells (HUVEC) and human dermal microvascular 
endothelial cells (MvEC) were analyzed by gelatin zymogra-
phy. The gelatin zymography without enterokinase showed a 
strong 64-kDa Ca2+-dependent gelatinolytic activity in the 
two conditioned media (data not shown). This enzyme was 
identified as pro-gelatinase A (pro-MMP-2) by Western blot-
ting analysis with anti-gelatinase-A antibody (data not 
shown). When the conditioned media were pretreated with 
enterokinase, which is the activator highly specific for trypsi-
nogen [16], the zymography showed a 25-kDa Ca2+-independ-
ent activity (Fig. 1A). This activity was completely inhibited 
by serine proteinase inhibitors such as diisopropyl fluorophos-
phate (DFP) and />-amidinophenyl methanesulfonyl fluoride 
O-APMSF) (data not shown). 
To date, four kinds of trypsinogen genes {trypsinogen-1, -2, 
-3, and -4) have been identified in humans [14,17,18], but no 
trypsinogens have been reported in vascular endothelial cells. 
To confirm that the 25-kDa enzyme was trypsin, Northern 
blotting analysis was carried out using a human trypsino-
gen-1 probe, which could detect both trypsinogen-1 and -2 
mRNAs because of their high homology (93% in nucleotide 
sequence). Both kinds of endothelial cells expressed a trypsi-
nogen gene transcript of about 850 bases (Fig. IB). To further 
determine if the transcript was trypsinogen-1 or -2, reverse 
transcription-polymerase chain reaction (RT-PCR) was car-
ried out. For the RT-PCR analysis, a PCR primer set was 
designed to have a Sad restriction site in the RT-PCR prod-
uct of trypsinogen-1 but not trypsinogen-2. The RT-PCR spe-
cifically amplified a 420-bp product from HUVEC RNA (Fig. 
1C). When the 420-bp DNA fragment was cloned and sub-
jected to nucleotide sequence analysis, all of three clones an-
alyzed had a sequence identical to human trypsinogen-2. 
Moreover, when treated with Sad restriction enzyme, the 
420-bp DNA fragment was not digested although the product 
amplified from trypsinogen-1 cDNA was split into two frag-
ments of 270 bp and 150 bp (Fig. 1C). This confirmed that at 
least the major type of the endothelial cell trypsinogen was 
trypsinogen-2. 
Next, expression of the trypsinogen gene was examined in 
HUVEC at various cell densities by Northern blotting (Fig. 
2A). HUVEC reached confluency between 7 and 9 days after 
seeding (Fig. 2B). The gene expression was maximal for initial 
3 days, when HUVEC grew in a logarithmic growth phase, 
and the level gradually decreased and reached nearly the basal 
level on day 7 (Fig. 2A,B). Thus, the expression of the trypsi-
nogen gene inversely correlated with the growth of the endo-
thelial cells. 
To reveal regulatory factors for the trypsinogen production, 
effects of various factors on HUVEC were examined. As 
shown in Fig. 3A,B, the tumor promoter TPA strongly stimu-
lated the expression of trypsinogen gene 6-12 h after the treat-
ment, increasing the enterokinase-dependent 25-kDa activity 
in the conditioned medium. When the enterokinase-treated 
conditioned media were analyzed by immunoblotting with 
rabbit polyclonal antibody against human trypsin, TPA-
treated HUVEC showed much stronger immunostained bands 
of 26 and 25 kDa, which appeared to correspond to trypsi-
nogen-2 and activated trypsin-2, respectively, than that of the 
control HUVEC, indicating that TPA increased the secretion 
of trypsinogen (Fig. 3C). These results suggest that protein 
kinase-C-dependent growth signal may up-regulate the tran-
scription of the trypsinogen gene directly or indirectly. How-
ever, tumor necrosis factor-oc, transforming growth factor-oc, 
and interleukin-lß showed no significant effect on the trypsi-
nogen expression in HUVEC (data not shown). Further ex-
periments are required to clarify the regulatory mechanism for 
the expression of trypsinogen-2 gene. 
3.2. Expression of trypsinogen in vivo 
To investigate the physiological and pathological roles of 
endothelial cell-derived trypsinogen-2, we examined its gene 
expression in vivo by in situ hybridization with a specific 
RNA probe for human trypsinogen-1 and -2 mRNAs. 
When a gastric carcinoma tissue was analyzed, strong staining 
of vascular endothelial cells was detected in small blood ves-
sels around a tumor nest (Fig. 4A). Such staining of endothe-
lial cells was not detected in the normal part of the tissue 
apart from the tumor nest (data not shown). A sense probe 
for trypsinogen-2 as a negative control never reacted with 
such endothelial cells (Fig. 4B). Similar positive signals in 
endothelial cells were detected in 6 cases of 7 gastric carcino-
Fig. 4. Detection of trypsinogen mRNA in vascular endothelial cells of human gastric carcinoma tissue and of DIC patient by in situ hybrid-
ization. All the tissues used were obtained by autopsy. Paraffin sections of the tissues were subjected to in situ hybridization for trypsinogen 
mRNA with antisense (a,c,d) and with sense (b) RNA probes, followed by counter-staimng with methylgreen. a,b: Gastric carcinoma tissue. In 
(a), strong staining for the trypsinogen message is seen in vascular endothelial cells (arrowheads) of a small vein at the distance of 2-3 mm 
from the edge of a tumor nest. However, no signal is seen in a similar vein (arrowheads) in the negative control with the sense probe (b). 
c: Kidney tissue from a DIC patient with rhabdomyolysis. d: Kidney tissue from a non-DIC patient with breast cancer. Arrowheads indicate 
positive staining for trypsinogen mRNA of vascular endothelial cells in (c). In (d) the signal for the message is undetectable. Bar: 60 urn. 
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mas analyzed, but undetectable in various normal tissues 
(data not shown). 
Vascular endothelial cells secrete various MMPs, such as 
gelatinase A, collagenase, stromelysin and gelatinase B, in 
latent proforms in response to various angiogenic factors in-
cluding TPA [7-9]. These MMPs are thought to play impor-
tant roles in tumor-associated angiogenesis and in tumor cell 
invasion through blood vessel wall. We have recently found 
that matrilysin (MMP-7) [19] and a small cell adhesion pro-
tein named TAF (tumor-derived adhesion factor) [20] are 
strongly induced in vascular endothelial cells of many human 
cancer tissues. Trypsin is known to degrade various extracel-
lular matrix proteins [10] and to activate the proforms of 
matrilysin and many other MMPs potently [21,22]. It seems 
very likely that trypsin produced by tumor cell-activated en-
dothelial cells contributes to tumor angiogenesis and tumor 
metastasis through pro-MMP activation and/or direct matrix 
degradation. In addition, we hypothesized that endothelial 
cell-derived trypsin might affect the blood coagulation system, 
because it is well known that tumor cells often activate the 
blood coagulation system, leading to intravascular thrombo-
sis, and that cancer is a frequent cause of disseminated intra-
vascular coagulation (DIC) [23]. To test this possibility, tryp-
sinogen-2 expression in DIC patients was examined by in situ 
hybridization analysis. As shown in Fig. 4C, obvious positive 
staining for trypsinogen mRNA was detected on the endothe-
lial cell layer of a small artery in the kidney. Similar positive 
signal was also seen in the the endothelial cells of intestinal 
wall from the same patient (data not shown). However, the 
signal for trypsinogen mRNA was hardly detected in a small 
artery in the kidney of a non-DIC patient (Fig. 4D). The 
signal for trypsinogen mRNA was detected in three cases of 
four DIC patients tested. 
The systemic activation of blood coagulation system results 
in multifocal fibrin clots. The activation of blood coagulation 
system in DIC is primarily dependent on activation of the 
extrinsic coagulation pathway [2]. To initiate this coagulation 
pathway, factor VII must be activated to Vila and then bind 
to tissue factor. So far, factor Xa, factor Xlla, thrombin and 
kallikrein have been listed as possible activators for factor VII 
[24,25]. Trypsin is known to activate factor VII to Vila [26]. 
We have obtained data that enterokinase-treated conditioned 
medium of HUVEC can activate factor VII to Vila (data not 
shown). Taken together, it seems possible that trypsin pro-
duced by activated endothelial cells initiates the extrinsic path-
way of blood coagulation. Very recently, Liu et al. have re-
ported that HUVEC are induced by IL-Iß or LPS to express a 
serine proteinase of about 30 kDa which can activate pro-
thrombin to thrombin [27]. It is also possible that trypsin 
acts as a prothrombin activator, although the expression of 
trypsin was significantly induced by neither IL-Iß nor LPS in 
our study. Furthermore, it is important to note that there is a 
family of proteolytically activated, G-protein-coupled recep-
tors with seven transmembrane domains. Thrombin receptor 
is activated by thrombin and mediates various cellular re-
sponses in platelets and vascular endothelial cells, such as 
platelet aggregation, cell growth, Ca2+ influx and chemotaxis 
[28]. Trypsin also activates the receptor but to a lesser extent 
than thrombin. Proteinase activated receptor 2 (PAR-2), a 
subtype of thrombin receptor, is effectively activated by tryp-
sin but not by thrombin [29]. The physiological activator for 
PAR-2 has not been identified yet. It also seems likely that the 
endothelial cell-derived trypsin functions as a natural activa-
tor for PAR-2 and thrombin receptor. 
There are few studies about expression and function of 
trypsin in non-pancreatic tissues. The present study first dem-
onstrates that vascular endothelial cells express trypsin-2 in 
vivo at least under some pathological conditions. On the other 
hand, our immunohistochemical study has shown that trypsin 
is produced by normal human bronchial epithelial cells as well 
as bronchial carcinoma cells [30]. More recently we have 
found by in situ hybridization analysis that trypsin is ex-
pressed by normal epithelial cells of various tissues such as 
esophagus, stomach and intestine (unpublished data). These 
results suggest that trypsin might play important roles in the 
expression of normal cellular functions in various tissues and 
cells. 
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